Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?

Simply Wall St.01-09

Soleno Therapeutics recently reported that pivotal Phase 3 results for VYKAT XR in Prader-Willi syndrome were published in the Journal of Clinical Endocrinology and Metabolism, reinforcing the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602377036?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-09 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602377036","market":"us","top_or_hot":-1,"title":"Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?","media":"Simply Wall St.","content":"<div>\n<p>Soleno Therapeutics recently reported that pivotal Phase 3 results for VYKAT XR in Prader-Willi syndrome were published in the Journal of Clinical Endocrinology and Metabolism, reinforcing the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/will-peerreviewed-vykat-xr-data-calm-safety-debate-and-chang\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 22:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/will-peerreviewed-vykat-xr-data-calm-safety-debate-and-chang><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Soleno Therapeutics recently reported that pivotal Phase 3 results for VYKAT XR in Prader-Willi syndrome were published in the Journal of Clinical Endocrinology and Metabolism, reinforcing the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/will-peerreviewed-vykat-xr-data-calm-safety-debate-and-chang\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/will-peerreviewed-vykat-xr-data-calm-safety-debate-and-chang","article_id":"2602377036","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-slno/soleno-therapeutics/news/will-peerreviewed-vykat-xr-data-calm-safety-debate-and-chang","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602377036","pubTimestamp":1767968898,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Soleno Therapeutics recently reported that pivotal Phase 3 results for VYKAT XR in Prader-Willi syndrome were published in the Journal of Clinical Endocrinology and Metabolism, reinforcing the clinical basis for its FDA approval as the first treatment for hyperphagia in this population.\nThe publication arrives amid short seller criticism of VYKAT XR’s safety and pricing, putting independently reviewed efficacy and safety data at the center of the debate.\nWith these peer-reviewed Phase 3...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLNO":"Soleno Therapeutics"},"translate_title":"同行评审的VYKAT XR数据能否平息安全性争论并改变Soleno Therapeutics(SLNO)的叙述？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLNO":1.5},"content_text":"Soleno Therapeutics recently reported that pivotal Phase 3 results for VYKAT XR in Prader-Willi syndrome were published in the Journal of Clinical Endocrinology and Metabolism, reinforcing the clinical basis for its FDA approval as the first treatment for hyperphagia in this population. The publication arrives amid short seller criticism of VYKAT XR’s safety and pricing, putting independently reviewed efficacy and safety data at the center of the debate. With these peer-reviewed Phase 3 findings now public, we’ll examine how the strengthened evidence base shapes Soleno’s investment narrative. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.AdvertisementWhat Is Soleno Therapeutics' Investment Narrative?To own Soleno here, you really have to believe in VYKAT XR as a durable, first‑in‑class commercial franchise in Prader‑Willi syndrome and in management’s ability to translate that into sustainable revenue growth and, eventually, consistent profitability. The JCEM Phase 3 publication directly feeds that belief: it puts independently reviewed efficacy and safety data into the public domain at a time when short sellers are attacking the drug’s risk‑benefit profile and pricing, and when a securities law investigation is adding another layer of uncertainty. In the near term, the main catalysts are U.S. launch execution, the EMA decision on DCCR in Europe, and how quickly the launch recovers from the post‑short‑report disruption. The key risks are drug safety perceptions, pricing pressure, and a rich valuation multiple that leaves little room for missteps.  \nYet one operational metric in particular could quickly change how this story is viewed. Despite retreating, Soleno Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other PerspectivesSLNO 1-Year Stock Price Chart Four fair value estimates from the Simply Wall St Community span roughly US$46 to about US$463 per share, underscoring how far apart expectations can be. Set against that wide spread, the recent JCEM publication and the focus on VYKAT XR’s safety, pricing and EU approval prospects could be exactly what shifts sentiment and, over time, the company’s operating profile. Readers should weigh these contrasting views before deciding how Soleno fits into their own portfolio.Explore 4 other fair value estimates on Soleno Therapeutics - why the stock might be worth over 10x more than the current price!Build Your Own Soleno Therapeutics NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Soleno Therapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Soleno Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Soleno Therapeutics' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 39 best rare earth metal stocks of the very few that mine this essential strategic resource.We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602377036","isCrawlerRequest":true}